Federal Register of Legislation
PB 38 of 2024
National Health (April 2024 Flow on price reductions for brands of combination items) (Exercise of Ministerial discretion) Determination 2024 National Health Act 1953
I, Nikolai Tsyganov, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care make this determination under subsection 99ADHB(6) of the National Health Act 1953.
Dated 27 March 2024
NIKOLAI TSYGANOV Assistant Secretary Pricing and PBS Policy Branch Technology Assessment and Access Division Department of Health and Aged Care
1 Name of Determination (1) This instrument is the National Health (April 2024 Flow on price reductions for brands of combination items) (Exercise of Ministerial discretion) Determination 2024.
(2) This instrument may also be cited as PB 38 of 2024.
2 Commencement This instrument commences the day after registration. 3 Definition
Note: A number of expressions used in this instrument are defined in Part VII the Act,
In this instrument:
Act means the National Health Act 1953. 4 Authority
This instrument is made under subsection 99ADHB(6) of the Act. 5 Brand of pharmaceutical item with approved ex-manufacturer price not reduced
I determine under subsection 99ADHB(6) of the Act that, for the purposes of subsection 99ADHB(2), the approved ex-manufacturer price, and each of the claimed prices (if applicable) of each brand of pharmaceutical item specified in column 2 in the table in Schedule 1 is not reduced on 1 April 2024. Schedule 1— Brand of pharmaceutical item with approved ex-manufacturer price not reduced
Column 1 Column 2 Item Brand of Pharmaceutical Item Drug Form Manner of administration Brand 1 Fosnetupitant with palonosetron Solution concentrate for I.V. infusion containing fosnetupitant 235 mg (as chloride hydrochloride) and palonosetron 250 microgram (as hydrochloride) Injection Akynzeo IV 2 Olmesartan with amlodipine and hydrochlorothiazide Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg Oral APO-Olmesartan/Amlodipine/HCTZ 40/10/12.5
We try to embed the page this law was scraped from. If the site blocks framing, you still get the link and a local excerpt.
Last checked with source on —
Checking whether the official page can be embedded…
Plain-English simplify of this law: a short summary, key points, and both sides of the argument. Generated on first view via Replicate, then cached. Vote on what helps your study.
No study brief is cached for this law yet. Sign up to generate a plain-English brief.
Sign up to generate